Kukje Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Kukje Pharma has a total shareholder equity of ₩89.9B and total debt of ₩29.0B, which brings its debt-to-equity ratio to 32.3%. Its total assets and total liabilities are ₩162.4B and ₩72.5B respectively. Kukje Pharma's EBIT is ₩4.3B making its interest coverage ratio 5. It has cash and short-term investments of ₩8.6B.
Key information
32.3%
Debt to equity ratio
₩29.00b
Debt
| Interest coverage ratio | 5x |
| Cash | ₩8.60b |
| Equity | ₩89.87b |
| Total liabilities | ₩72.54b |
| Total assets | ₩162.42b |
Recent financial health updates
Recent updates
Kukje Pharma's (KRX:002720) Strong Earnings Are Of Good Quality
Nov 21
Kukje Pharma Co., Ltd.'s (KRX:002720) 28% Price Boost Is Out Of Tune With Revenues
Aug 08What Kukje Pharma Co., Ltd.'s (KRX:002720) 27% Share Price Gain Is Not Telling You
Jun 24Kukje Pharma Co., Ltd.'s (KRX:002720) Share Price Not Quite Adding Up
Mar 20Kukje Pharma's (KRX:002720) Solid Profits Have Weak Fundamentals
Mar 20If You Had Bought Kukje Pharma (KRX:002720) Stock A Year Ago, You Could Pocket A 121% Gain Today
Mar 19These 4 Measures Indicate That Kukje Pharma (KRX:002720) Is Using Debt Reasonably Well
Feb 21What Type Of Shareholders Own The Most Number of Kukje Pharma Co., Ltd. (KRX:002720) Shares?
Jan 25
Kukje Pharma Co., Ltd.'s (KRX:002720) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Dec 30Investors Who Bought Kukje Pharma (KRX:002720) Shares Five Years Ago Are Now Up 227%
Dec 04Financial Position Analysis
Short Term Liabilities: A002720's short term assets (₩53.3B) exceed its short term liabilities (₩23.6B).
Long Term Liabilities: A002720's short term assets (₩53.3B) exceed its long term liabilities (₩49.0B).
Debt to Equity History and Analysis
Debt Level: A002720's net debt to equity ratio (22.7%) is considered satisfactory.
Reducing Debt: A002720's debt to equity ratio has reduced from 50.4% to 32.3% over the past 5 years.
Debt Coverage: A002720's debt is not well covered by operating cash flow (13%).
Interest Coverage: A002720's interest payments on its debt are well covered by EBIT (5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 09:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kukje Pharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|